Role of SDF1a pathway in prostate cancer relapse and metastasis post-radiotherapy
SDF1a通路在前列腺癌放疗后复发和转移中的作用
基本信息
- 批准号:8493794
- 负责人:
- 金额:$ 30.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-19 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:AMD3100ApoptosisBiologyBlood VesselsBone MarrowBone Marrow TransplantationCXCL12 geneCXCR4 ReceptorsCXCR4 geneCancer RelapseCell SurvivalCellsChalconeClinicCoculture TechniquesDiseaseDistantDistant MetastasisDoseExcisionGeneticGenetic ModelsGrowthHumanImaging TechniquesImmunohistochemistryImplantIn VitroInfiltrationInflammatoryLabelLuciferasesMalignant neoplasm of prostateMeasuresMediatingMethodologyModelingMusMyelogenousMyeloid CellsNeoplasm MetastasisOperative Surgical ProceduresPC3 cell linePathway interactionsPrimary NeoplasmProductionProstate carcinomaRadiationRadiation therapyReagentRecruitment ActivityRelapseResearchResistanceRoleSystemTestingTransgenic MiceTranslatingTumor EscapeUp-RegulationWorkbioluminescence imagingcancer cellcancer recurrencecell motilitychemokinecombinatorialcytokinedensityefficacy testingimprovedin vivoinhibitor/antagonistirradiationmigrationmouse modelnew growthnovel strategiespre-clinicalprostate cancer cellprostate cancer modelresearch studyresistance mechanismsmall hairpin RNAstandard caretumortumor growth
项目摘要
DESCRIPTION (provided by applicant): It is increasingly accepted that certain cytokines may promote tumor growth and metastasis either by directly increasing cancer cell survival and invasion or by recruiting tumor-promoting inflammatory cells. Local irradiation is associated with increased cytokine production and with infiltration of inflammatory cells in tumors. Thus, these mechanisms may be more broadly relevant for tumor escape from therapy. This concept is strongly supported by results from models of tumor relapse after radiotherapy, and may be directly related to upregulation of stromal-derived factor 1 alpha (SDF11, also known as CXCL12) after local irradiation. Here, we propose to study the role of the SDF11 receptors CXCR4 and CXCR7 in local relapse and metastasis in a model of locally advanced prostate cancer recurrence after radiation therapy. In Specific Aim 1, we will examine the impact on prostate cancer cell viability and migration of (i) inhibiting CXCR4 or CXCR7 in PCa cells after irradiation; and (ii) co-culturing the irradiated prostate cancer cells with non-irradiated bone marrow-derived cells (BMDCs). In Specific Aim 2, we will evaluate (i) the impact of CXCR4 or CXCR7 inhibition in prostate cancer cells on tumor relapse after irradiation in vivo; and (ii) the role of SDF11/CXCR4 pathway in bone marrow-derived cell (BMDC) recruitment after irradiation, and the contribution of BMDCs to the vasculature of tumors after radiotherapy. In Specific Aim 3, we will test the efficacy of pharmacologic agents targeting CXCR4 or SDF11 with radiation therapy in orthotopic prostate cancer models. This proposal will uncover mechanisms of resistance to standard treatment (radiotherapy) in prostate cancer by revealing the role of SDF11 pathway and myeloid BMDC incorporation during prostate cancer relapse. Having established (i) relevant preclinical methodology to model prostate cancer in mice and measure the proposed parameters, and (ii) the necessary expertise on prostate cancer, BMDC and SDF11 biology, we think that our team is capable to successfully complete these studies. In addition, this work may be rapidly translated in the clinic by integrating CXCR4 inhibition with clinically available agents (e.g., plerixafor) with combinatorial approaches with radiation.
描述(由申请人提供):越来越接受的是,某些细胞因子可以通过直接增加癌细胞存活和侵袭或募集促肿瘤炎性细胞来促进肿瘤生长和转移。局部照射与肿瘤中细胞因子的产生增加和炎性细胞浸润有关。因此,这些机制可能与肿瘤摆脱治疗更为广泛。放疗后肿瘤复发模型的结果得到了强烈支持,并且可能与局部照射后基质来源1α(SDF11,也称为CXCL12)的上调直接相关。在这里,我们建议研究SDF11受体CXCR4和CXCR7在放射治疗后局部晚期前列腺癌复发模型中局部复发和转移的作用。在特定目标1中,我们将检查对PROSTATE癌细胞活力的影响以及(i)抑制PCA细胞中CXCR4或CXCR7的迁移; (ii)将辐照的前列腺癌细胞与未辐照的骨髓衍生细胞(BMDC)共同培养。在特定目标2中,我们将评估(i)CXCR4或CXCR7在体内辐射后抑制前列腺癌细胞对肿瘤复发的影响; (ii)辐照后SDF11/CXCR4途径在骨髓衍生的细胞(BMDC)募集中的作用,以及放射治疗后BMDC对肿瘤的脉管系统的贡献。在特定目标3中,我们将测试针对原位前列腺癌模型中靶向CXCR4或SDF11的药理学剂的功效。该建议将通过揭示前列腺癌和髓样BMDC在前列腺癌复发期间的作用,从而发现前列腺癌中标准治疗(放射疗法)的耐药性机制。建立了(i)相关的临床前方法来模拟小鼠前列腺癌并测量所提出的参数,以及(ii)前列腺癌,BMDC和SDF11生物学的必要专业知识,我们认为我们的团队能够成功完成这些研究。此外,这项工作可以通过将CXCR4抑制与临床上可用的药物(例如Plerixafor)与辐射的组合方法相结合,从而在诊所中迅速翻译。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dan Gabriel Duda其他文献
Dan Gabriel Duda的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dan Gabriel Duda', 18)}}的其他基金
Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer
确定早期三阴性乳腺癌的最佳放疗剂量和分割与术前免疫化疗相结合
- 批准号:
10512391 - 财政年份:2023
- 资助金额:
$ 30.54万 - 项目类别:
Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC
基于放射和 CSPG4 特异性 CAR T 细胞的组合疗法用于 TNBC 的体内治疗
- 批准号:
10290575 - 财政年份:2021
- 资助金额:
$ 30.54万 - 项目类别:
Vascularized tumor explants for drug testing
用于药物测试的血管化肿瘤外植体
- 批准号:
10317398 - 财政年份:2021
- 资助金额:
$ 30.54万 - 项目类别:
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy
免疫治疗期间肿瘤生物标志物的多重时域荧光断层扫描
- 批准号:
10372211 - 财政年份:2021
- 资助金额:
$ 30.54万 - 项目类别:
Vascularized tumor explants for drug testing
用于药物测试的血管化肿瘤外植体
- 批准号:
10424580 - 财政年份:2021
- 资助金额:
$ 30.54万 - 项目类别:
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy
免疫治疗期间肿瘤生物标志物的多重时域荧光断层扫描
- 批准号:
10983625 - 财政年份:2021
- 资助金额:
$ 30.54万 - 项目类别:
Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC
基于放射和 CSPG4 特异性 CAR T 细胞的组合疗法用于 TNBC 的体内治疗
- 批准号:
10447683 - 财政年份:2021
- 资助金额:
$ 30.54万 - 项目类别:
Vascularized tumor explants for drug testing
用于药物测试的血管化肿瘤外植体
- 批准号:
10642870 - 财政年份:2021
- 资助金额:
$ 30.54万 - 项目类别:
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy
免疫治疗期间肿瘤生物标志物的多重时域荧光断层扫描
- 批准号:
10600866 - 财政年份:2021
- 资助金额:
$ 30.54万 - 项目类别:
Role of SDF1a pathway in prostate cancer relapse and metastasis post-radiotherapy
SDF1a通路在前列腺癌放疗后复发和转移中的作用
- 批准号:
8678707 - 财政年份:2011
- 资助金额:
$ 30.54万 - 项目类别:
相似国自然基金
基于内质网应激—细胞凋亡—盆腔微血管内皮损伤探讨月经病实寒证生物学机制及温经汤干预研究
- 批准号:82174426
- 批准年份:2021
- 资助金额:55.00 万元
- 项目类别:面上项目
活细胞实时原位脂质定量检测方法研究鞘磷脂循环在肿瘤细胞凋亡过程中的分子机制
- 批准号:91953107
- 批准年份:2019
- 资助金额:60.0 万元
- 项目类别:重大研究计划
CCN1诱导食管癌细胞凋亡的分子生物学途径
- 批准号:81960445
- 批准年份:2019
- 资助金额:35 万元
- 项目类别:地区科学基金项目
复杂疾病高通量数据的多尺度建模与网络分析
- 批准号:61802125
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
冷大气压等离子体射流作用黑色素瘤皮肤组织模型的生物学效应及其机理研究
- 批准号:51707149
- 批准年份:2017
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Efferocytosis by Bone Marrow Stromal Cells and Bone Aging
骨髓基质细胞的胞吞作用和骨老化
- 批准号:
10629389 - 财政年份:2022
- 资助金额:
$ 30.54万 - 项目类别:
Overcoming Leukemia Chemoresistance in the Central Nervous System
克服中枢神经系统的白血病化疗耐药性
- 批准号:
10591475 - 财政年份:2020
- 资助金额:
$ 30.54万 - 项目类别:
Overcoming Leukemia Chemoresistance in the Central Nervous System
克服中枢神经系统的白血病化疗耐药性
- 批准号:
10357911 - 财政年份:2020
- 资助金额:
$ 30.54万 - 项目类别:
Investigation of therapeutic potential of exogenous ubiquitin following myocardial ischemia/reperfusion injury
外源性泛素治疗心肌缺血/再灌注损伤潜力的研究
- 批准号:
10371145 - 财政年份:2019
- 资助金额:
$ 30.54万 - 项目类别:
Investigation of therapeutic potential of exogenous ubiquitin following myocardial ischemia/reperfusion injury
外源性泛素治疗心肌缺血/再灌注损伤潜力的研究
- 批准号:
10619513 - 财政年份:2019
- 资助金额:
$ 30.54万 - 项目类别: